Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2009 Results
Date:4/29/2009

G&A

expenses in the first quarter of 2009 relative to the first quarter

of 2008 is primarily due to lower stock-based compensation and

commercial expenses.

Employee stock-based compensation expense recorded in the first

quarter of 2009 totaled $2.3 million. Of these non-cash charges,

$0.2 million was recorded as R&D expense and $2.1 million was

recorded as G&A expense. For the fourth quarter of 2008 and the

first quarter of 2008, total stock-based compensation expense was

$0.7 million and $5.1 million, respectively. The increase in stock-

based compensation expense in the first quarter of 2009 relative to

the fourth quarter of 2008 is the result of the fourth quarter

expense encompassing the net effect of stock-based compensation for

the period for existing employees, reduced by the reversal of stock-

based compensation charges resulting from the cancellation of

unvested options in connection with the workforce reduction which

occurred in the fourth quarter of 2008. The decrease in stock-based

compensation expense in the first quarter of 2009 relative to the

first quarter of 2008 is primarily due to no options being granted

in the first quarter of 2009.

* Cash and marketable securities decreased by $3.8 million during the

first quarter of 2009. Changes included $6.5 million of net losses

offset by increases in accrued expenses and accounts payable of

$0.1 million, decreases in prepaid expenses of $0.2 million and

$2.4 million in non-cash depreciation, amortization, and stock-based

compensation expense.

* Vanda's cash, cash equivalents and marketab
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
6. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
8. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
9. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
10. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
11. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , ... August 27, 2015 , ... ... Medicine, recently presented new data on the relationship of genetics and hypertension at ... Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts ...
(Date:8/26/2015)... VANCOUVER , Aug. 26, 2015 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... continue pre-clinical activities with respect to our Oral ... of a contract manufacturer," said Andrew Rae ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, ... the development and manufacture of highly valued cardiac markers used in early detection ... expertise with protein chemistry has led to the development and commercialization of important ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... CAMBRIDGE, Mass., Jan. 12 Cequent Pharmaceuticals, a pioneer ... treatments to prevent and treat human disease, announced that ... officer. Mr. Hibben comes to Cequent from Coley Pharmaceutical ... business development and alliance management and played a key ...
... Human Genome Sciences, Inc. (Nasdaq: HGSI ... Annual JPMorgan Healthcare Conference will be webcast and may ... )A member of Human Genome Sciences, senior management ... Wednesday, January 14, 2009 at 7:30 am Pacific Time ...
... to Enable Stockholders to Determine Fate of Company,s ... Avigen Stockholders Extraordinary Risk/Reward OpportunitySAN FRANCISCO, Jan. 9 ... affiliates ("BVF") today announced that it has requested ... ("Avigen") (Nasdaq: AVGN ) call a ...
Cached Biology Technology:Cequent Names Ted Hibben Chief Business Officer 2Cequent Names Ted Hibben Chief Business Officer 3Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 2Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 3Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 4Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 5
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den ... bliver afholdt af BGI fra den 22. - 25. oktober ... Konferencen fejrer sin 10-års fødselsdag i år. Siden ... mest indflydelsesrige årlige møder på ,omik,-feltet, og er en ... ICG-10 fokuserer på nylige gennembrud og ...
(Date:7/31/2015)... 2015 La 10 th International Conference on ... BGI del 22 al 25 de octubre de 2015 en ... la conferencia celebra su décimo aniversario. Desde su inauguración en ... las reuniones anuales más influyentes del mundo en el campo ... entusiastas y mejores a nivel científico. ICG-10 ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... new method that could give a deeper insight into evolutional ... in EPJ Data Science . Paolo Masucci from the ... UK, and colleagues identified the segregation of genes that a ... exchange of genes, or gene flow, between populations of a ...
... WILMINGTON, N.C., Dec. 10, 2012 Chiltern International Limited ... Dr. Cedric Burg and James Gunter have joined Chiltern, ... clients, needs and to strengthen our Global Clinical Development ... to announce that Dr. Cedric Burg has been appointed ...
... means of controlling urban insect pests by using ultrasonic ... few of these devices have been demonstrated as being ... or ants. Despite the lack of evidence for the ... and new versions targeting bed bugs are readily available. ...
Cached Biology News:Tracking gene flow in marine plant evolution 2Chiltern Welcomes Cedric Burg And James Gunter 2
Transcription factor Sp2. [Source:Uniprot/SWISSPROT;Acc:Q02086] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
E2F2 protein...
Anti-DDDDK-Tag (Enterokinase Cleavage Site), Agarose Conjugate Research Focus: tag Storage: 4C Shipping Temperature: 4C...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Biology Products: